Subscribe to RSS
DOI: 10.1055/a-2229-3489
Serum Lipid Level in Evaluating Chinese Pancreatic Neuroendocrine Neoplasms: A Retrospective Study
Funding information This work was supported by the Science Foundation Project of Ili and Jiangsu Joint Institute of Health (Grant No. yl2020lhms05), Wuxi “Taihu talent plan” for the excellent medical expert team (Grant No. 2021–9), the New Clinical Treatment Technology Research Fund BE2019753 (ZC19), National Natural Science Foundation of China (Grant No. 82373180). New Clinical TreatmentTechnology Research Fund — BE2019753 (ZC19) Wuxi “Taihu talent plan” for the excellent medical expert team — 2021–9 National Natural Science Foundation of China — http://dx.doi.org/10.13039/501100001809; 82373180Science Foundation Project of Ili & Jiangsu Joint Institute of Health — yl2020lhms05
Abstract
Background Pancreatic neuroendocrine neoplasms (p-NENs) are relatively rare and highly heterogeneous. Dyslipidemia may be related to the risk of developing p-NENs, although dyslipidemia in patients with p-NENs is rarely reported. In this study, the clinical characteristics of p-NENs patients with different lipid levels and their prognostic value in p-NENs patients were evaluated.
Methods Patients (n=211) with p-NENs hospitalized at Jiangsu Neuroendocrine Tumor Centre of Jiangsu Province Hospital from December 2018 to December 2022 were enrolled. Clinical data related to p-NENs were collected. Based on the EGA database, the related lipoprotein, low-density lipoprotein receptor (LDLR) and high-density lipoprotein binding protein (HDLBP) mRNA in p-NENs and paratumoral tissues and the follow-up information of p-NENs were evaluated.
Results A total of 175 p-NENs patients ultimately met the inclusion criteria. The ki67 index was higher in p-NENs patients with elevated lipid with the proportion of≥5, and in those with AJCC stage III and stage IV than p-NENs patients with low-level lipid. In p-NENs patients, the expression of HDLBP mRNA was downregulated in p-NENs tissues compared to the paratumoral tissues. Survival analysis showed that serum lipids had no effect on the prognosis of p-NENs; however, high LDLR level p-NENs were at the risk of poor survival.
Conclusion Serum lipid level in p-NENs can affect the grading and staging, but the correlation with the prognosis of p-NENs is not significant. However, dyslipidemia may be a potential predictor of p-NENs.
† Co-first authors: Danyang Gu, Bingyan Xue, Guoqin Zhu
Publication History
Received: 10 September 2023
Received: 01 December 2023
Accepted: 28 November 2023
Accepted: 14 December 2023
Accepted Manuscript online:
14 December 2023
Article published online:
24 January 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68: 471-487
- 2 Dasari A, Shen C, Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335-1342
- 3 Clift AK, Kidd M, Bodei L. et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology 2020; 110: 444-476
- 4 Gorelik M, Ahmad M, Grossman D. et al. Nonfunctioning incidental pancreatic neuroendocrine tumors: Who, when, and how to Treat?. Surg Clin North Am 2018; 98: 157-167
- 5 Ito T, Igarashi H, Nakamura K. et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol 2015; 50: 58-64
- 6 Fan J-H, Zhang Y-Q, Shi S-S. et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China. Oncotarget 2017; 8: 71699-71708
- 7 Vernieri C, Casola S, Foiani M. et al. Targeting cancer metabolism: Dietary and pharmacologic interventions. Cancer Discov 2016; 6: 1315-1333
- 8 Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 2016; 16: 732-749
- 9 Modica R, La Salvia A, Liccardi A. et al. Lipid metabolism and homeostasis in patients with neuroendocrine neoplasms: From risk factor to potential therapeutic target. Metabolites 2022; 12: 1057-1067
- 10 Andrew JH, Shilpa RN, Lisa MB. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer 2021; 21: 753-766
- 11 Salem ME, Puccini A, Grothey A. et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res 2018; 16: 805-812
- 12 Chee WF, Azhar A. Fatty acid synthase: An emerging target in cancer. Molecules 2020; 25: 3935
- 13 Zhong S, Li L, Zhang YL. et al. Acetaldehyde dehydrogenase 2 interactions with LDLR and AMPK regulate foam cell formation. J Clin Invest 2019; 129: 252-267
- 14 Xia YR, Klisak I, Sparkes RS. et al. Localization of the gene for high-density lipoprotein binding protein (HDLBP) to human chromosome 2q37. Genomics 199 16: 524-525
- 15 Wen LY, Ling W, Wen QH. et al. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth. Oncol Rep 2014; 31: 2328-2334
- 16 Yoshiaki S, Artur R, Jörg K. Lipid metabolism and lipid droplets in pancreatic cancer and stellate cells. Cancers 2017; 10: 3